Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors(354 views) De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S
Clin Nucl Med (ISSN: 1536-0229, 0363-3976, 0363-9762), 2013; 38(5): 354-358.
Keywords: 111in-Octreotide, 18f-Fdg-Pet Ct, Functional Imaging, Multimodality Imaging, Thymic Epithelial Tumors, Thymic Neuroendocrine Tumors, Fluorodeoxyglucose F 18, Pentetreotide, Pentetreotide In 111, Adult, Article, Cancer Risk, Clinical Evaluation, Computer Assisted Emission Tomography, Controlled Study, Correlational Study, Drug Uptake, Epithelium Tumor, Female, Human, Primary Tumor, Statistical Significance, Thymic Epithelium Tumor, Thymoma, World Health Organization, Middle Aged, Neoplasms, Glandular And Epithelial, Positron-Emission Tomography And Computed Tomography, Retrospective Studies, Roc Curve, Thymus Neoplasms, Emission-Computed, Single-Photon,
Affiliations: *** IBB - CNR ***
Department of Biomorphological and Functional Sciences, University of Naples Federico II, Via Pansini 5 Edificio 10, 80131 Napoli, Italy
Institute of Biostructures and Bioimages, National Research Council, Italy
Department of Endocrinology and Molecular and Clinical Oncology, University of Naples Federico II, Italy
Rare Tumors Excellence Center, University Hospital Federico II, Naples, Italy
Department of Medicine and Surgery, University of Salerno, Salerno, Italy
References: Srirajaskanthan, R., Toubanakis, C., Dusmet, M., A review of thymic tumors (2008) Lung Cancer, 60, pp. 4-1
Marom, E. M., Imaging thymoma (2010) J Thorac Oncol, 5 (SUPPL. 4), pp. S296-S303
Liu, R. S., Yeh, S. H., Huang, M. H., Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: A preliminary report (1995) Eur J Nucl Med, 22, pp. 1402-1407
Sasaki, M., Kuwabara, Y., Ichiya, Y., Akashi, Y., Yoshida, T., Nakagawa, M., Murayama, S., Masuda, K., Differential diagnosis of thymic tumors using a combination of 11C- methionine PET and FDG PET (1999) Journal of Nuclear Medicine, 40 (10), pp. 1595-1601
Sung, Y. M., Lee, K. S., Kim, B. T., F-18-FDG PET/CT of thymic epithelial tumors: Usefulness for distinguishing and staging tumor subgroups (2006) J Nucl Med, 47, pp. 1628-1634
Endo, M., Nakagawa, K., Ohde, Y., Utility of F-18DG-PET for differentiating the grade of malignancy in thymic epithelial tumors (2008) Lung Cancer, 61, pp. 350-355
Terzi, A., Bertolaccini, L., Rizzardi, G., Usefulness of 18-F FDG PET/CT in the pre-treatment evaluation of thymic epithelial neoplasms (2011) Lung Cancer, 74, pp. 239-243
Kaira, K., Endo, M., Abe, M., Biologic correlation of 2- [F-18] -fluoro- 2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors (2010) J Clin Oncol., 28, pp. 3746-3753
Nakajo, M., Kajiya, Y., Tani, A., F-18DG PET for grading malignancy in thymic epithelial tumors: Significant differences in F-18DG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: Preliminary study (2012) Eur J Radiol, 81, pp. 146-151
Masaoka, A., Staging system of thymoma (2010) J Thorac Oncol, 5 (SUPPL. 4), pp. S304-S312
Bombardieri, E., Ambrosini, V., Aktolun, K., 111In-pentetreotide scintigraphy: Procedure guidelines for tumour imaging (2010) Eur J Nucl Med Mol Imaging, 37, pp. 1441-1448
Lastoria, S., Vergara, E., Palmieri, G., Acampa, W., Varrella, P., Caraco, C., Bianco, R. A., Salvatore, M., In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (1998) Journal of Nuclear Medicine, 39 (4), pp. 634-639
Marienhagen, J., Schalke, B., Aebert, H., Held, P., Eilles, C., Bogdahn, U., Somatostatin receptor scintigraphy in thymoma imaging method and clinical application (1999) Pathology Research and Practice, 195 (8), pp. 575-581
Lin, K., Nguyen, Ba. D., Ettinger, D. S., Chin, B. B., Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma (1999) Clinical Nuclear Medicine, 24 (1), pp. 24-28. , DOI 10. 1097/00003072-199901000-00006
Miederer, M., Seidl, S., Buck, A., Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT (2009) Eur J Nucl Med Mol Imaging, 36, pp. 48-52
Carrasquillo, J. A., Chen, C. C., Molecular imaging of neuroendocrine tumors (2010) Semin Oncol, 37, pp. 662-679
Ferone, D., Pivonello, R., Van Martin Hagen, P., Dalm, V. A. S. H., Lichtenauer-Kaligis, E. G. R., Waaijers, M., Van Koetsveld, P. M., Hofland, L. J., Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes (2002) American Journal of Physiology - Endocrinology and Metabolism, 283 (5), pp. E1056-E1066
Palmieri, G., Lastoria, S., Colao, A., Vergara, E., Varrella, P., Biondi, E., Selleri, C., Salvatore, M., Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone (1997) New England Journal of Medicine, 336 (4), pp. 263-265. , DOI 10. 1056/NEJM199701233360405
Loehrer Sr., P. J., Wang, W., Johnson, D. H., Ettinger, D. S., Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group phase II trial (2004) Journal of Clinical Oncology, 22 (2), pp. 293-299. , DOI 10. 1200/JCO. 2004. 02. 047
Kelly, R. J., Petrini, I., Rajan, A., Thymic malignancies: From clinical management to targeted therapies (2011) J Clin Oncol, 29, pp. 4820-4827
Liu, R.S., Yeh, S.H., Huang, M.H., Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: A preliminary report (1995) Eur J Nucl Med, 22, pp. 1402-1407
Sung, Y.M., Lee, K.S., Kim, B.T., F-18-FDG PET/CT of thymic epithelial tumors: Usefulness for distinguishing and staging tumor subgroups (2006) J Nucl Med, 47, pp. 1628-1634
Carrasquillo, J.A., Chen, C.C., Molecular imaging of neuroendocrine tumors (2010) Semin Oncol, 37, pp. 662-679
Loehrer Sr., P.J., Wang, W., Johnson, D.H., Ettinger, D.S., Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group phase II trial (2004) Journal of Clinical Oncology, 22 (2), pp. 293-299. , DOI 10.1200/JCO.2004.02.047
Kelly, R.J., Petrini, I., Rajan, A., Thymic malignancies: From clinical management to targeted therapies (2011) J Clin Oncol, 29, pp. 4820-4827
Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors
PURPOSE: This study aimed to test the role of combined imaging with F-FDG-PET/CT and In-octreotide SPECT in characterizing thymic epithelial tumors (TETs). METHODS: We evaluated 20 patients with newly diagnosed TETs who had undergone concomitant F-FDG-PET/CT and In-octreotide SPECT. Thymic epithelial tumors were classified by World Health Organization (WHO) as low-risk thymomas (5), high-risk thymomas (4), and thymic carcinomas (11, among which 6 neuroendocrine tumors). Patients were staged according to Masaoka system. F-FDG-PET/CT was performed and SUVmax of primary tumors was recorded. In-octreotide SPECT of the thorax was performed, and tumor-to-background ratio was determined on the 24-hour coronal sections. RESULTS: All patients showed increased F-FDG uptake in mediastinal lesions. SUVmax were significantly correlated with WHO classification (r = 0. 66, P < 0. 01) and with Masaoka stage (r = 0. 60, P < 0. 01). SUVmax of low-risk thymomas (mean [SD], 2. 87 [0. 83]) were significantly lower than those of high-risk thymomas (mean [SD], 7. 21 [1. 73], P < 0. 01) and of thymic carcinomas (mean [SD], 9. 39 [5. 80], P < 0. 05), whereas no significant difference was found between high-risk thymomas and thymic carcinomas. SUVmax of all high-risk thymomas and thymic carcinomas was 4. 5 or greater. All primary tumors were detected by In-octreotide SPECT, and tumor-to-background ratios ranged between 1. 67 and 10. 10. No statistically significant correlation was found between tumor-to-background ratios and WHO classification (r = 0. 24, P = 0. 36) and Masaoka stages (r = 0. 31, P = 0. 23). However tumor-to-background ratios of thymic neuroendocrine tumors (mean [SD], 5. 71 [3. 09]) were significantly higher than those of all other TETs with SUVmax of 4. 5 or greater (mean [SD], 2. 41 [0. 56]; P < 0. 05). CONCLUSIONS: F-FDG-PET/CT scan allows to differentiate high-risk epithelial tumors and thymic carcinomas from low-risk thymomas, whereas In-octreotide SPECT may identify neuroendocrine tumors among those showing high F-FDG uptake. 2013 by Lippincott Williams & Wilkins
Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors